Rvl Pharmaceuticals Plc (RVLP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 8,258 | 8,832 | 9,807 | 10,022 | 8,448 |
| Cost of Goods | 1,946 | 2,299 | 2,560 | 2,525 | 2,227 |
| Gross Profit | 6,312 | 6,533 | 7,247 | 7,497 | 6,221 |
| Operating Expenses | 29,279 | 17,123 | 32,355 | 21,944 | 21,572 |
| Operating Income | -22,021 | -10,291 | -24,548 | -13,922 | -15,124 |
| Interest Expense | 13 | 26 | 15 | 1,132 | 978 |
| Other Income | -1,968 | -1,237 | 5,959 | 671 | 4,273 |
| Pre-tax Income | -24,002 | -11,554 | -18,604 | -14,383 | -11,829 |
| Income Tax | -113 | 58 | -285 | 63 | 277 |
| Net Income Continuous | -23,889 | -11,612 | -18,319 | -14,446 | -12,106 |
| Net Income | $-23,889 | $-11,612 | $-18,319 | $-14,446 | $-12,106 |
| EPS Basic Total Ops | -0.24 | -0.12 | -0.20 | -0.16 | -0.14 |
| EPS Basic Continuous Ops | -0.24 | -0.12 | -0.19 | -0.16 | -0.14 |
| EPS Diluted Total Ops | -0.24 | -0.12 | -0.20 | -0.16 | -0.14 |
| EPS Diluted Continuous Ops | -0.24 | -0.12 | -0.19 | -0.16 | -0.14 |
| EPS Diluted Before Non-Recurring Items | -0.13 | -0.12 | -0.18 | -0.16 | -0.19 |
| EBITDA(a) | $-8,027 | $-10,198 | $-8,075 | $-13,827 | $-16,000 |